Condition

Gene Abnormality

ClinicalTrials.gov condition label

Clinical trials8

Recruiting1

Common interventions7

Lead sponsors shown7

Clinical trials

8 shown

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided TherayNCT03192501 · 2017-07-01

INDIcators for Clarifying the bAckground of exTreme Obesity in childRenNCT06420622 · 2024-04-15

Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural MesotheliomaNCT04823741 · 2022-02-11

Endometrial Heparin-binding Epidermal Growth Factor ExpressionNCT04175002 · 2019-08-01

B2 Adrenergic Receptor Gene Polymorphism in Bronchial AsthmaNCT03118869 · 2017-04-01

Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast CancerNCT05427617 · 2016-12-01

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast CancerNCT05079074 · 2016-12-01

Genotyping of Non-small Cell Lung CancerNCT02002117 · 2012-01-01

Common interventions

Case groupDRUG1 Control groupDRUG1 ctDNA testingDIAGNOSTIC_TEST1 DNA massOTHER1 inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.DRUG1 PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMAGENETIC1 utrogestanDRUG1

Leading sponsors

Hunan Cancer Hospital2 Assiut University1 Hospices Civils de Lyon1 National Taiwan University Hospital1 National University of Malaysia1 Second Affiliated Hospital of Guangzhou Medical University1 University of Leipzig1

Trial status mix

UNKNOWN5

COMPLETED2

RECRUITING1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.